Diabetes drug combo may shield hearts: new trial launches
NCT ID NCT03878706
First seen Mar 24, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study looks at whether combining two common diabetes medications (GLP-1 agonists and SGLT2 inhibitors) can improve heart function and blood vessel health in people with type 2 diabetes who are at high risk for heart problems. About 240 participants will be split into four groups, each receiving different treatments, and their heart health will be tracked over 12 months. The goal is to find the best way to protect the heart in people with diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
"Attikon" University General Hospital
RECRUITINGAthens, Attica, 12462, Greece
Contact
Conditions
Explore the condition pages connected to this study.